Aptose Biosciences (TSE:APS) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$2.18 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 101 shares trading hands.

Analysts Set New Price Targets

Separately, Alliance Global Partners downgraded shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

Aptose Biosciences Stock Down 2.2%

The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37. The firm has a 50 day moving average of C$2.18 and a two-hundred day moving average of C$1.96. The firm has a market capitalization of C$5.61 million, a price-to-earnings ratio of 3.19 and a beta of -1.05.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.